Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST
- Registry ID
- EUCTR2005-004837-16
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Novartis Pharma GmbH
- Start date
- 2006-08-17
- Completion date
- 2012-11-28
- Last update
- 2026-08-16
Conditions
- gastrointestinal stromal tumors (GIST)
Summary
To assess the response to treatment with RAD001 plus Glivec® at 4 months. Response is defined as progression-free survival (PFS) at 4 months.
Locations
View on source registry